Figure 5
Figure 5. Reduced organ damage and RBC sickling in SCD mice treated with RN-1. (A-B) SCD mice treated with RN-1 exhibited modestly reduced splenomegaly. The size (A) and the weight (B) of spleens are depicted (*P < .05 vs untreated SCD mice). (C) Wright-Giemsa staining of peripheral blood smears of SCD mice before and after daily RN-1 administration for 1 month. Arrows indicate sickled cells. The average percentage of sickle cells in each group is presented as the mean ± SD (n = 4-6 mice per group) (*P < .05; **P < .01). (D) H&E staining of liver and spleen sections from untreated or RN-1–treated SCD mice.

Reduced organ damage and RBC sickling in SCD mice treated with RN-1. (A-B) SCD mice treated with RN-1 exhibited modestly reduced splenomegaly. The size (A) and the weight (B) of spleens are depicted (*P < .05 vs untreated SCD mice). (C) Wright-Giemsa staining of peripheral blood smears of SCD mice before and after daily RN-1 administration for 1 month. Arrows indicate sickled cells. The average percentage of sickle cells in each group is presented as the mean ± SD (n = 4-6 mice per group) (*P < .05; **P < .01). (D) H&E staining of liver and spleen sections from untreated or RN-1–treated SCD mice.

Close Modal

or Create an Account

Close Modal
Close Modal